Eli Lilly's weight-loss drug Zepbound (tirzepatide) reduces sleep apnea episodes by up to 63% in late-stage trials.

Eli Lilly's weight-loss drug Zepbound has been proven to reduce sleep apnea episodes, paving the way for its expanded use. The GLP-1 drug reduced the frequency of irregular breathing episodes by up to 63% across two late-stage trials. Zepbound, also known as tirzepatide, has shown potential medical benefits beyond diabetes and weight loss, and the trial results add to a growing body of related clinical evidence.

April 21, 2024
10 Articles

Further Reading